Aurinia Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUPH and other ETFs, options, and stocks.

About AUPH

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada. 

CEO
Kevin C. Tang
CEOKevin C. Tang
Employees
128
Employees128
Headquarters
Edmonton, Alberta
HeadquartersEdmonton, Alberta
Founded
1993
Founded1993
Employees
128
Employees128

AUPH Key Statistics

Market cap
2.07B
Market cap2.07B
Price-Earnings ratio
7.54
Price-Earnings ratio7.54
Dividend yield
Dividend yield
Average volume
1.45M
Average volume1.45M
High today
$15.74
High today$15.74
Low today
$15.06
Low today$15.06
Open price
$15.20
Open price$15.20
Volume
1.26M
Volume1.26M
52 Week high
$16.54
52 Week high$16.54
52 Week low
$6.83
52 Week low$6.83

Stock Snapshot

The current Aurinia Pharmaceuticals(AUPH) stock price is $15.63, with a market capitalization of 2.07B. The stock trades at a price-to-earnings (P/E) ratio of 7.54.

During the trading session on 2026-04-03, Aurinia Pharmaceuticals(AUPH) shares reached a daily high of $15.74 and a low of $15.06. At a current price of $15.63, the stock is +3.8% higher than the low and still -0.7% under the high.

Trading volume for Aurinia Pharmaceuticals(AUPH) stock has reached 1.26M, versus its average volume of 1.45M.

The stock's 52-week range extends from a low of $6.83 to a high of $16.54.

The stock's 52-week range extends from a low of $6.83 to a high of $16.54.

AUPH News

TipRanks 4d
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 7d
Assessing Aurinia Pharmaceuticals Valuation As LUPKYNIS Growth And Pipeline Prospects Shape Expectations

Advertisement What Aurinia Pharmaceuticals offers and where it stands today Aurinia Pharmaceuticals (AUPH) focuses on therapies for autoimmune diseases, ancho...

Assessing Aurinia Pharmaceuticals Valuation As LUPKYNIS Growth And Pipeline Prospects Shape Expectations

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
42.9%
Sell
0%

People also own

Based on the portfolios of people who own AUPH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.